Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123372
Filing Date
2024-11-07
Accepted
2024-11-07 16:15:28
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q atha-20240930.htm   iXBRL 10-Q 2361816
2 EX-31.1 atha-ex31_1.htm EX-31.1 15942
3 EX-31.2 atha-ex31_2.htm EX-31.2 15831
4 EX-32.1 atha-ex32_1.htm EX-32.1 8958
5 EX-32.2 atha-ex32_2.htm EX-32.2 8001
6 GRAPHIC img106170215_0.jpg GRAPHIC 87901
  Complete submission text file 0000950170-24-123372.txt   7973186

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20240930.xsd EX-101.SCH 987077
72 EXTRACTED XBRL INSTANCE DOCUMENT atha-20240930_htm.xml XML 1133379
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

EIN.: 453368487 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39503 | Film No.: 241435962
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)